About Unicycive
Unicycive is a company based in San Francisco (United States) founded in 2016. Unicycive has raised $1.55 million across 5 funding rounds from investors including Octagon Capital Advisors, Great Point Partners and Logos Capital. The company has 22 employees as of December 31, 2024. Unicycive offers products and services including Oxylanthanum Carbonate (OLC) and UNI-494. Unicycive operates in a competitive market with competitors including Calliditas Therapeutics, Akebia Therapeutics, Alebund, Aurinia Pharmaceuticals and Renalys, among others.
- Headquarter San Francisco, United States
- Employees 22 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Unicycive Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$36.73 M (USD)-20.25as on Dec 31, 2024
-
EBITDA
-$31.69 M (USD)-54.66as on Dec 31, 2024
-
Total Equity Funding
$1.55 M (USD)
in 5 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Mar 13, 2024
-
Investors
Octagon Capital Advisors
& 6 more
-
Employee Count
22
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Unicycive
Unicycive is a publicly listed company on the NASDAQ with ticker symbol UNCY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Unicycive
Unicycive offers a comprehensive portfolio of products and services, including Oxylanthanum Carbonate (OLC) and UNI-494.
Treats hyperphosphatemia using proprietary nanoparticle technology.
Targets mitochondria for acute kidney injury treatment.
People of Unicycive
Unlock access to complete
Funding Insights of Unicycive
Unicycive has successfully raised a total of $1.55M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Unicycive
Unicycive has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Octagon Capital Advisors, Great Point Partners and Logos Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in healthcare startups are managed by Octagon Capital Advisors.
|
Locked | Locked | Locked | |
|
Private equity firm focused on company buyouts
|
Locked | Locked | Locked | |
|
Private equity fund focused on the biotechnology sector
|
Locked | Locked | Locked |
Investor details for Unicycive
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Unicycive
Investment portfolio details for Unicycive
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Unicycive
Detailed financials for Unicycive
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Unicycive Comparisons
Peer comparison for Unicycive
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Unicycive
Unicycive operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Akebia Therapeutics, Alebund, Aurinia Pharmaceuticals and Renalys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| Locked | Locked | Locked |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| Locked | Locked | Locked |
Therapeutics for various kidney diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
|
| Locked | Locked | Locked |
Therapeutics for renal diseases are developed and launched by Renalys.
|
Detailed competitors of Unicycive
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Unicycive
Complete news archive for Unicycive
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Unicycive
Unicycive was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Unicycive is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Unicycive is a funded company, having raised a total of $1.55M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Unicycive is 22.
Unicycive was founded in 2016 and is based in San Francisco, United States. Focus is placed on developing small molecule therapies targeting kidney diseases within the biotechnology sector. The lead product, UNI 494, is under investigation for both acute and chronic kidney conditions. Oxylanthanum Carbonate is also being advanced for managing hyperphosphatemia. Operations center on therapeutic innovation for renal health challenges.
Unicycive's top competitors include Calliditas Therapeutics, Akebia Therapeutics and Gennova.
Unicycive offers Oxylanthanum Carbonate (OLC) and UNI-494.
Yes, Unicycive is publicly traded on NASDAQ under the ticker symbol UNCY.
Unicycive has 7 investors. Key investors include Octagon Capital Advisors, Great Point Partners, Logos Capital, Nantahala Capital Management, and Velan Capital.
The ticker symbol of Unicycive is UNCY on NASDAQ.